Concepedia

Anil K. Padyana

AK

Statistics

Publications

22

Citations

1.7K

H-Index

19

Active since

2001

Affiliations

Agios Pharmaceuticals (United States)(Current)

Boehringer Ingelheim (Japan)

Rockefeller University

Boehringer Ingelheim (United States)

Indian Institute of Science Bangalore

Anil K. Padyana is an author at Agios Pharmaceuticals (United States) specializing in life sciences, drug discovery, and structural biology.

ORCID

Publications per year

2001–2023

22

Publications

22

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations

Katharine Yen, Jeremy Travins, Fang Wang et al. · Cancer Discovery · 2017 · 458 citations · Full text

, , +17

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

Zenon Konteatis, Erin Artin, Brandon Nicolay et al. · ACS Medicinal Chemistry Letters · 2020 · 186 citations · Full text

, , +16

Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase

Anil K. Padyana, Lei Jin, Giovanni Cianchetta et al. · Nature Communications · 2019 · 155 citations · Full text

, , +17

Crystal Structure of a Light-Harvesting Protein C-Phycocyanin from Spirulina platensis

Anil K. Padyana, Vadiraja B. Bhat, K. M. Madyastha et al. · Biochemical and Biophysical Research Communications · 2001 · 143 citations

, , +13

Structural Basis for Autoinhibition and Mutational Activation of Eukaryotic Initiation Factor 2α Protein Kinase GCN2*[boxs]

Anil K. Padyana, Hongfang Qiu, Antonina Roll‐Mecak et al. · Journal of Biological Chemistry · 2005 · 134 citations · Full text

, , +17

1–5 of 22